Author

Xin V. Wang

Institutions: Harvard University, Dana-Farber Cancer Institute

Observed institutions: Mayo Clinic, Kaiser Permanente, Harvard University, University of California, Irvine, Dana-Farber Cancer Institute, Stanford University

OpenAlex ID: A5088288352

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

2019 · Tait D. Shanafelt, Xin V. Wang, et al. · New England Journal of Medicine · 751

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease

2018 · Mark R. Litzow, Xin V. Wang, et al. · American Journal of Hematology · 27

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

2022 · Richard D. Gelber, Xin V. Wang, et al. · European Journal of Cancer · 21

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

2020 · Chezi Ganzel, Xin V. Wang, et al. · British Journal of Haematology · 18

Works count: 4

Citation count: 817

H-index: 4

I10-index: 4